

**SUPPLEMENTAL DISCLOSURE**  
**Material Corporate Developments**

**SB Technology Holdings, Inc.**

(formerly VG Life Sciences, Inc.) — OTC: VGLSD

447 Broadway, 2nd Floor, Unit 103

New York, New York 10013

Telephone: 877-646-4833

Website: [www.vglscorp.com](http://www.vglscorp.com) | Email: [info@vglscorp.com](mailto:info@vglscorp.com)

Standard Industrial Classification (SIC): 6719

**Supplemental Information Report — Material Corporate Developments**

Dated June 15, 2026

Covering Material Events From and After June 8, 2026

This Supplemental Disclosure is furnished by SB Technology Holdings, Inc. (formerly known as VG Life Sciences, Inc.) (the “Company,” “Pubco,” “SBTH,” “we,” “our,” or “us”) through the OTC Markets disclosure and news service as a Supplemental Information report to provide a consolidated description of the material corporate developments that have occurred from and after June 8, 2026. This Supplemental Disclosure should be read together with, and supplements, the Company’s prior disclosure statements posted through the OTC Markets disclosure and news service, including the Company’s disclosure statement for the period ended March 31, 2026, the Company’s Supplemental Disclosure — Change in Control Event dated June 10, 2026, and the Company’s Supplemental Disclosure — Material Related Party Transaction (Tradaverse Note) dated June 4, 2026. Each of the items below is addressed to the best of the Company’s ability and to the extent applicable.

**1. Change in Control and Acquisition of Canvas 2709, LLC (June 8, 2026).**

On June 8, 2026 (the “Effective Date”), the Company entered into a Membership Interest Exchange and Change of Control Agreement (the “Agreement”) by and among the Company; Canvas 2709, LLC, a Florida limited liability company (“Canvas”); Selkirk Global Holdings, LLC, a Washington limited liability company (“Selkirk”); and the holders of all of the issued and outstanding membership interests of Canvas (the “Members”). Under the Agreement, the Company acquired one hundred percent (100%) of the membership interests of Canvas, such that Canvas became a wholly-owned subsidiary of the Company. In consideration for those membership interests, Selkirk — the record holder of 95,858,282 shares of the Company’s Series A Preferred Stock (the “Consideration Shares”), which carry super-voting rights and are convertible into common stock under the applicable Certificate of Designation — transferred and delivered the Consideration Shares to The David and Jessika Contreras Living Trust (the “Trust”), as the recipient designated on behalf of the Members.

The transfer of the super-voting Consideration Shares to the Trust vested voting and economic control of the Company in the Trust (and, through it, in its trustee and beneficiaries) and resulted in a change in a majority of the Company’s Board of Directors, thereby effecting the change of control. Canvas’s principal asset is fee simple title to improved real property located at 7311 NW 12th Street, Unit #15, Miami, Florida 33125 (Doral Flex II Condominium, Unit 15; Folio/Parcel No. 30-3035-014-0150; approximately 1,509 square feet). Because only the membership interests of Canvas were transferred and title to the real property remains vested in Canvas, no deed or other instrument of conveyance of the real property was executed or recorded. The consideration paid for the membership interests of Canvas consisted solely of the equity securities described above; no cash, promissory note, or other consideration was paid by the Company. The Agreement provides that if the Members fail to deliver the membership interests of Canvas free and clear within sixty (60) calendar days of the Effective Date, or otherwise breach their covenants, the Consideration Shares shall be forfeited and returned to Selkirk pursuant to an undated, irrevocable Stock Power, and the

related board and officer appointments shall be rescinded. A complete description of the change in control is set forth in the Company's Supplemental Disclosure — Change in Control Event dated June 10, 2026.

## **2. Changes in Officers and Directors; Information Statement on Schedule 14F-1.**

In connection with the change of control, the Company's prior sole director and officer, Paul Strickland, tendered his resignation from all positions with the Company, and Jessika Contreras was appointed as the Company's sole director and as President, Chief Executive Officer, Secretary, and Treasurer. Jessika Contreras serves as Trustee of the Trust and, in that capacity, holds sole voting and dispositive power over the Consideration Shares; David Contreras and Jessika Contreras are the beneficiaries of the Trust. To the extent required, the Company has prepared and is disseminating an Information Statement on Schedule 14F-1 with respect to the change in a majority of the Company's Board of Directors, and the change in the composition of the Board is intended to take effect in accordance with the ten (10) day period contemplated by Rule 14f-1.

## **3. Approval of Amendment to the Articles of Incorporation — Change of Corporate Name to “Biomolecular Life, Inc.” (June 15, 2026).**

By Action by Written Consent of the Sole Director dated June 15, 2026, and by Written Consent of Stockholders dated June 15, 2026, the Company's sole director and the holder of a majority of the voting power of the Company's issued and outstanding capital stock approved an amendment to the Company's Amended and Restated Articles of Incorporation to change the name of the Company from “SB Technology Holdings, Inc.” to “Biomolecular Life, Inc.” (the “Name Change”), in order to reflect the Company's business and strategic direction following the change of control. The stockholder approval was provided by The David and Jessika Contreras Living Trust, the record holder of all 95,858,282 issued and outstanding shares of Series A Preferred Stock, representing in excess of ninety-nine percent (99%) of the total voting power of the Company's issued and outstanding capital stock, acting by written consent pursuant to Section 607.0704 of the Florida Business Corporation Act. The Name Change will become effective upon the filing of Articles of Amendment with the Florida Department of State, Division of Corporations, or upon such later effective date as may be specified therein, and is subject to processing by the Financial Industry Regulatory Authority (“FINRA”) before becoming effective in the market.

## **4. Approval of Amendment to the Articles of Incorporation — Reduction of Authorized Capital Stock (June 15, 2026).**

By the same Action by Written Consent of the Sole Director dated June 15, 2026, and Written Consent of Stockholders dated June 15, 2026, the Company's sole director and majority stockholder also approved an amendment to the Company's Amended and Restated Articles of Incorporation to reduce the total number of authorized shares of the Company's common stock, par value \$0.0001 per share, from 40,000,000,000 shares to 400,000,000 shares (the “Authorized Capital Reduction”). After giving effect to the Authorized Capital Reduction, the Company will be authorized to issue a total of 500,000,000 shares of capital stock, consisting of 400,000,000 shares of common stock, par value \$0.0001 per share, and 100,000,000 shares of preferred stock, par value \$0.0001 per share. The number of authorized shares of preferred stock (100,000,000) and the par value of the Company's capital stock (\$0.0001 per share) are unchanged, and, except for the reduction in the number of authorized shares of common stock, the designations, powers, preferences, rights, qualifications, limitations, and restrictions of the Company's capital stock remain unchanged. The Authorized Capital Reduction was approved in order to more appropriately align the Company's authorized capital with its capital structure following the 1-for-20,000 reverse stock split of the Company's common stock that became effective on April 16, 2026, after which there are 1,061,595 shares of common stock issued and outstanding, and to reduce the costs and fees associated with the Company's authorized capital. The Authorized Capital Reduction will become effective upon the filing of Articles of Amendment with the Florida Department of State, Division of Corporations, or upon such later effective

date as may be specified therein. The Authorized Capital Reduction does not effect a reverse split of, or otherwise change, the number of shares of common stock presently issued and outstanding.

#### **5. Anticipated Regulatory Filings and Corporate Actions.**

In connection with the foregoing, the Company intends to: (i) file Articles of Amendment to its Amended and Restated Articles of Incorporation with the Florida Department of State, Division of Corporations, to effect the Name Change and the Authorized Capital Reduction; (ii) submit an Issuer Company-Related Action Notification and all related documentation to FINRA pursuant to FINRA Rule 6490 in connection with the Name Change and any related change to the Company's trading symbol; (iii) obtain a new CUSIP number for the Company's common stock through CUSIP Global Services; and (iv) provide notice of, and documentation relating to, the foregoing to OTC Markets Group Inc., to Liberty Stock Transfer, Inc., as the Company's transfer agent, and to such other parties as may be necessary or appropriate, and update the Company's OTC Markets Issuer Profile to reflect the new officers and directors, principal address, and beneficial ownership. The Name Change, the related change in trading symbol, and the new CUSIP number will not become effective in the market until processed by FINRA, and there can be no assurance as to the timing of any such processing.

#### **6. Related-Party Transaction and Conflicts of Interest.**

As more fully described in the Company's Supplemental Disclosure — Change in Control Event dated June 10, 2026, the change of control is a related-party transaction within the meaning of Section 607.0832 of the Florida Business Corporation Act. Paul Strickland served as Secretary and a director of the Company and is the Managing Member of Selkirk, which held the Consideration Shares transferred to the Trust. The material facts of this relationship and of Mr. Strickland's interest were disclosed to, and the transaction was reviewed and approved as fair to, and in the best interests of, the Company and its stockholders by, the disinterested members of the Company's Board, with Mr. Strickland abstaining to the extent of his interest. No third-party finder, broker, or promoter participated in, assisted in, organized, or brokered the transaction.

#### **7. Forward-Looking Statements and Risk Factors.**

This Supplemental Disclosure contains forward-looking statements that involve risks and uncertainties, including statements regarding the Company's intention to complete the Name Change and the Authorized Capital Reduction, to make the anticipated regulatory filings, and to integrate Canvas and its real property asset. Actual results may differ materially from those expressed or implied. Among other things: the Name Change, the related trading symbol change, and the new CUSIP number are subject to acceptance and processing by FINRA, the Florida Department of State, CUSIP Global Services, and other third parties, and the timing and completion of such actions are not within the Company's sole control; the change of control remains subject to forfeiture and rescission if the Members fail to deliver the membership interests of Canvas free and clear within sixty (60) days of the Effective Date or otherwise breach their covenants; and the value ultimately realized by the Company from Canvas and its real property asset is subject to numerous risks and uncertainties. The Company undertakes no obligation to update any forward-looking statement except as required by applicable rules.

#### **8. Additional Information.**

Additional information regarding the matters described herein, including the Membership Interest Exchange and Change of Control Agreement dated June 8, 2026, the Action by Written Consent of the Sole Director dated June 15, 2026, and the Written Consent of Stockholders dated June 15, 2026, is maintained in the Company's records and, where applicable, in the Company's filings and postings through the OTC Markets disclosure and news service.

### **Certification**

The undersigned officer of SB Technology Holdings, Inc. hereby certifies that, to the best of her knowledge and belief, the information contained in this Supplemental Disclosure is true, correct, and complete in all material respects.

Date: June 15, 2026

/s/ Jessika Contreras  
Jessika Contreras  
President and Chief Executive Officer and Sole Director,  
SB Technology Holdings, Inc.

*(Digital signatures should appear as “/s/ [OFFICER NAME].”)*